{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:33:42Z","timestamp":1791945222438,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7618","license":[{"start":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T00:00:00Z","timestamp":1472601600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T00:00:00Z","timestamp":1472601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2016,9,1]]},"DOI":"10.1038\/nature19323","type":"journal-article","created":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T12:28:21Z","timestamp":1472560101000},"page":"50-56","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2937,"title":["The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"537","author":[{"given":"Jeff","family":"Sevigny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Bussi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dunstan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Salloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianle","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"O\u2019Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahin","family":"Arastu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowmya","family":"Chollate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie S.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Quintero-Monzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Scannevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Moore","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Engber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaming","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvydas","family":"Mikulskis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger M.","family":"Nitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Sandrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,31]]},"reference":[{"key":"BFnature19323_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 297, 353\u2013356 (2002)","journal-title":"Science"},{"key":"BFnature19323_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy, J. A. & Higgins, G. A. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256, 184\u2013185 (1992)","journal-title":"Science"},{"key":"BFnature19323_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/cpt.200","volume":"98","author":"C Ising","year":"2015","unstructured":"Ising, C., Stanley, M. & Holtzman, D. M. Current thinking on the mechanistic basis of Alzheimer\u2019s and implications for drug development. Clin. Pharmacol. Ther. 98, 469\u2013471 (2015)","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnature19323_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/ana.24001","volume":"74","author":"DJ Selkoe","year":"2013","unstructured":"Selkoe, D. J. The therapeutics of Alzheimer\u2019s disease: where we stand and where we are heading. Ann. Neurol. 74, 328\u2013336 (2013)","journal-title":"Ann. Neurol."},{"key":"BFnature19323_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"JL Cummings","year":"2014","unstructured":"Cummings, J. L., Morstorf, T. & Zhong, K. Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res. Ther. 6, 37 (2014)","journal-title":"Alzheimers Res. Ther."},{"key":"BFnature19323_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody, R. S. et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N. Engl. J. Med. 370, 311\u2013321 (2014)","journal-title":"N. Engl. J. Med."},{"key":"BFnature19323_CR7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway, S. et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N. Engl. J. Med. 370, 322\u2013333 (2014)","journal-title":"N. Engl. J. Med."},{"key":"BFnature19323_CR8","unstructured":"Ferrero, J. et al. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer\u2019s disease. Alzheimers Dement (N Y) (in the press)"},{"key":"BFnature19323_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/WAD.0000000000000144","volume":"30","author":"J Sevigny","year":"2016","unstructured":"Sevigny, J. et al. Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial. Alzheimer Dis. Assoc. Disord. 30, 1\u20137 (2016)","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"BFnature19323_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2967\/jnumed.112.109009","volume":"54","author":"SM Landau","year":"2013","unstructured":"Landau, S. M. et al. Amyloid-\u03b2 imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J. Nucl. Med. 54, 70\u201377 (2013)","journal-title":"J. Nucl. Med."},{"key":"BFnature19323_CR11","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0196-9781(02)00261-9","volume":"23","author":"WA Banks","year":"2002","unstructured":"Banks, W. A. et al. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer\u2019s disease. Peptides 23, 2223\u20132226 (2002)","journal-title":"Peptides"},{"key":"BFnature19323_CR12","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1096\/fj.06-6463fje","volume":"20","author":"Y Levites","year":"2006","unstructured":"Levites, Y. et al. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer\u2019s disease mouse models. FASEB J. 20, 2576\u20132578 (2006)","journal-title":"FASEB J."},{"key":"BFnature19323_CR13","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard, F. et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916\u2013919 (2000)","journal-title":"Nat. Med."},{"key":"BFnature19323_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/JAD-2011-110977","volume":"28","author":"B Bohrmann","year":"2012","unstructured":"Bohrmann, B. et al. Gantenerumab: a novel human anti-A\u03b2 antibody demonstrates sustained cerebral amyloid-\u03b2 binding and elicits cell-mediated removal of human amyloid-\u03b2. J. Alzheimers Dis. 28, 49\u201369 (2012)","journal-title":"J. Alzheimers Dis."},{"key":"BFnature19323_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne, V. L. et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 12, 357\u2013367 (2013)","journal-title":"Lancet Neurol."},{"key":"BFnature19323_CR16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","volume":"69","author":"S Ostrowitzki","year":"2012","unstructured":"Ostrowitzki, S. et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol. 69, 198\u2013207 (2012)","journal-title":"Arch. Neurol."},{"key":"BFnature19323_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","volume":"11","author":"R Sperling","year":"2012","unstructured":"Sperling, R. et al. Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 11, 241\u2013249 (2012)","journal-title":"Lancet Neurol."},{"key":"BFnature19323_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 7, 367\u2013385 (2011)","journal-title":"Alzheimers Dement."},{"key":"BFnature19323_CR19","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3174\/ajnr.A3500","volume":"34","author":"J Barakos","year":"2013","unstructured":"Barakos, J. et al. MR imaging features of amyloid-related imaging abnormalities. AJNR Am. J. Neuroradiol. 34, 1958\u20131965 (2013)","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"BFnature19323_CR20","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/j.jalz.2012.11.010","volume":"9","author":"W Zago","year":"2013","unstructured":"Zago, W. et al. Vascular alterations in PDAPP mice after anti-A\u03b2 immunotherapy: Implications for amyloid-related imaging abnormalities. Alzheimers Dement. 9 (Suppl), S105\u2013S115 (2013)","journal-title":"Alzheimers Dement."},{"key":"BFnature19323_CR21","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1523\/JNEUROSCI.5077-10.2011","volume":"31","author":"A Wang","year":"2011","unstructured":"Wang, A., Das, P., Switzer, R. C., III, Golde, T. E. & Jankowsky, J. L. Robust amyloid clearance in a mouse model of Alzheimer\u2019s disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J. Neurosci. 31, 4124\u20134136 (2011)","journal-title":"J. Neurosci."},{"key":"BFnature19323_CR22","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1093\/brain\/awn261","volume":"131","author":"D Boche","year":"2008","unstructured":"Boche, D. et al. Consequence of Abeta immunization on the vasculature of human Alzheimer\u2019s disease brain. Brain 131, 3299\u20133310 (2008)","journal-title":"Brain"},{"key":"BFnature19323_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrm2101","volume":"8","author":"C Haass","year":"2007","unstructured":"Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101\u2013112 (2007)","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"BFnature19323_CR24","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.3233\/JAD-2012-129001","volume":"33","author":"R Kayed","year":"2013","unstructured":"Kayed, R. & Lasagna-Reeves, C. A. Molecular mechanisms of amyloid oligomers toxicity. J. Alzheimers Dis. 33 (Suppl 1), S67\u2013S78 (2013)","journal-title":"J. Alzheimers Dis."},{"key":"BFnature19323_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nn.3028","volume":"15","author":"I Benilova","year":"2012","unstructured":"Benilova, I., Karran, E. & De Strooper, B. The toxic A\u03b2 oligomer and Alzheimer\u2019s disease: an emperor in need of clothes. Nat. Neurosci. 15, 349\u2013357 (2012)","journal-title":"Nat. Neurosci."},{"key":"BFnature19323_CR26","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1073\/pnas.0811698106","volume":"106","author":"RM Koffie","year":"2009","unstructured":"Koffie, R. M. et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl Acad. Sci. USA 106, 4012\u20134017 (2009)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature19323_CR27","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","volume":"14","author":"GM Shankar","year":"2008","unstructured":"Shankar, G. M. et al. Amyloid-beta protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory. Nat. Med. 14, 837\u2013842 (2008)","journal-title":"Nat. Med."},{"key":"BFnature19323_CR28","doi-asserted-by":"publisher","first-page":"6176","DOI":"10.1038\/ncomms7176","volume":"6","author":"C Condello","year":"2015","unstructured":"Condello, C., Yuan, P., Schain, A. & Grutzendler, J. Microglia constitute a barrier that prevents neurotoxic protofibrillar A\u03b242 hotspots around plaques. Nat. Commun. 6, 6176 (2015)","journal-title":"Nat. Commun."},{"key":"BFnature19323_CR29","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1073\/pnas.1017033108","volume":"108","author":"M Jin","year":"2011","unstructured":"Jin, M. et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc. Natl Acad. Sci. USA 108, 5819\u20135824 (2011)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature19323_CR30","doi-asserted-by":"publisher","first-page":"P508","DOI":"10.1016\/j.jalz.2013.05.1061","volume":"9","author":"K Kastanenka","year":"2013","unstructured":"Kastanenka, K. et al. Amelioration of calcium dyshomeostasis by immunotherapy with BIIB037 in Tg2576 mice. Alzheimers Dement. 9, P508 (2013)","journal-title":"Alzheimers Dement."},{"key":"BFnature19323_CR31","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1074\/jbc.R115.702704","volume":"291","author":"HH Jarosz-Griffiths","year":"2016","unstructured":"Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V. & Hooper, N. M. Amyloid-\u03b2 receptors: the good, the bad, and the prion protein. J. Biol. Chem. 291, 3174\u20133183 (2016)","journal-title":"J. Biol. Chem."},{"key":"BFnature19323_CR32","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/jnr.23510","volume":"93","author":"R Morkuniene","year":"2015","unstructured":"Morkuniene, R. et al. Small A\u03b21-42 oligomer-induced membrane depolarization of neuronal and microglial cells: role of N-methyl-d-aspartate receptors. J. Neurosci. Res. 93, 475\u2013486 (2015)","journal-title":"J. Neurosci. Res."},{"key":"BFnature19323_CR33","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.neuron.2013.06.036","volume":"79","author":"JW Um","year":"2013","unstructured":"Um, J. W. et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer a\u03b2 oligomer bound to cellular prion protein. Neuron 79, 887\u2013902 (2013)","journal-title":"Neuron"},{"key":"BFnature19323_CR34","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1212\/WNL.0b013e31828ab2c9","volume":"80","author":"CA Derby","year":"2013","unstructured":"Derby, C. A. et al. Screening for predementia AD: time-dependent operating characteristics of episodic memory tests. Neurology 80, 1307\u20131314 (2013)","journal-title":"Neurology"},{"key":"BFnature19323_CR35","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","volume":"9","author":"B Dubois","year":"2010","unstructured":"Dubois, B. et al. Revising the definition of Alzheimer\u2019s disease: a new lexicon. Lancet Neurol. 9, 1118\u20131127 (2010)","journal-title":"Lancet Neurol."},{"key":"BFnature19323_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 263\u2013269 (2011)","journal-title":"Alzheimers Dement."},{"key":"BFnature19323_CR37","unstructured":"Eli Lilly and Company. Amyvid Prescribing Information. http:\/\/www.lilly.com . (2013)"},{"key":"BFnature19323_CR38","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark, C. M. et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol. 11, 669\u2013678 (2012)","journal-title":"Lancet Neurol."},{"key":"BFnature19323_CR39","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/nm783","volume":"8","author":"C Hock","year":"2002","unstructured":"Hock, C. et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 8, 1270\u20131275 (2002)","journal-title":"Nat. Med."},{"key":"BFnature19323_CR40","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.4049\/jimmunol.143.8.2595","volume":"143","author":"MH Tao","year":"1989","unstructured":"Tao, M. H. & Morrison, S. L. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143, 2595\u20132601 (1989)","journal-title":"J. Immunol."},{"key":"BFnature19323_CR41","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1073\/pnas.94.4.1550","volume":"94","author":"K Johnson-Wood","year":"1997","unstructured":"Johnson-Wood, K. et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl Acad. Sci. USA 94, 1550\u20131555 (1997)","journal-title":"Proc. Natl Acad. Sci. USA"}],"updated-by":[{"DOI":"10.1038\/nature22809","type":"addendum","label":"Addendum","source":"publisher","updated":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:00:00Z","timestamp":1498089600000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature19323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature19323","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature19323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T18:17:11Z","timestamp":1692469031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature19323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,31]]},"references-count":41,"journal-issue":{"issue":"7618","published-print":{"date-parts":[[2016,9,1]]}},"alternative-id":["BFnature19323"],"URL":"https:\/\/doi.org\/10.1038\/nature19323","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726696119.793524558","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.726696119.793528776","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.726696119.793522850","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,31]]},"assertion":[{"value":"20 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S., P.C., T.B., P.H.W., L.W., R.D., T.C., Y.L., J.O., F.Q., M.A., M.L., S.C., M.S.B., O.Q.-M., R.H.S., H.M.A., T.E., K.R., J.F., Y.H., A.M. and A.S. are current or former employees and\/or shareholders of Biogen. J.S. is an employee of F. Hoffmann-La Roche Ltd., Basel, Switzerland; R.D. is an employee of AbbVie Inc., Worcester, Massachusetts, USA; M.A. is an employee of Substantial Living, San Francisco, California, USA; M.L. is an employee of Novartis, Cambridge, Massachusetts, USA; S.C. is an employee of SynteractHCR, Carlsbad, California, USA; O.Q.-M. is an employee of Shire, Lexington, Massachusetts, USA; R.H.S. and K.R. are employees of Yumanity Therapeutics, Cambridge, Massachusetts, USA; T.E. is an employee of Takeda Pharmaceuticals, Cambridge, Massachusetts, USA; J.F. is retired. M.M., J.G., C.H. and R.M.N. are employees and shareholders of Neurimmune. S.S. was a site investigator for the PRIME study and received consultation fees from Biogen, and has received research support from Functional Neuromodulation, Merck, Genentech, Roche, Lilly, and Avid Radiopharmaceuticals, and consultation fees from Merck, Piramal, Lilly, Genentech, and Roche. He owns no stock options or royalties. Biogen has filed and licensed certain patent applications pertaining to Aducanumab.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}